Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe.
Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke.
Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension. The report analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.
Covered in this report:
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.
Global Pulmonary Hypertension Market has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
To Request Sample Copy of This Report:
http://www.radiantinsights.com/research/pulmonary-hypertension-global-market-research-2015-2019#tabs-4
Key vendors
Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke.
Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension. The report analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.
Covered in this report:
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.
Global Pulmonary Hypertension Market has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
To Request Sample Copy of This Report:
http://www.radiantinsights.com/research/pulmonary-hypertension-global-market-research-2015-2019#tabs-4
Key vendors
- Actelion
- Bayer
- GlaxoSmithKline
- United Therapeutics
Other prominent vendros
- Aires Pharmaceuticals
- Arena Pharmaceuticals
- Bial
- DEKA
- Dong-A ST
- Gilead
- Merck
- Northern Therapeutics
- Novartis
- Pfizer
- PhaseBio
Key market driver
- Growing incidence of pulmonary hypertension
- For a full, detailed list, view our report
Key market challenge
- Patent expiry
- For a full, detailed list, view our report
Key market trend
- Increased focus on combination therapies
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No comments:
Post a Comment